{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:38:49Z","timestamp":1791833929700,"version":"4.3.4"},"reference-count":135,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019418","name":"NIHR Maudsley Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018952","name":"Birmingham Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018952","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.cld.2026.04.013","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T22:26:16Z","timestamp":1780957576000},"page":"715-750","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Primary Sclerosing Cholangitis"],"prefix":"10.1016","volume":"30","author":[{"given":"Nasir","family":"Hussain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palak J.","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2026.04.013_bib1","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0140-6736(25)02582-6","article-title":"Primary sclerosing cholangitis","volume":"407","author":"von Seth","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2026.04.013_bib2","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/apt.15148","article-title":"Systematic review with meta-analysis: risk factors for recurrent primary sclerosing cholangitis after liver transplantation","volume":"49","author":"Steenstraten","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"24","key":"10.1016\/j.cld.2026.04.013_bib3","first-page":"00165","article-title":"Immunopathogenesis of primary biliary cholangitis, primary sclerosing cholangitis and autoimmune hepatitis: themes and concepts","volume":"S0016-5085","author":"Trivedi","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2026.04.013_bib4","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1136\/gutjnl-2020-322362","article-title":"Recent advances in clinical practice: epidemiology of autoimmune liver diseases","volume":"70","author":"Trivedi","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.cld.2026.04.013_bib5","article-title":"Epidemiology, natural history, and outcomes of primary sclerosing cholangitis: a systematic review of population-based studies","author":"Trivedi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.04.013_bib6","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1053\/j.gastro.2020.05.049","article-title":"Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel diseases, based on sex, race, and age","volume":"159","author":"Trivedi","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2026.04.013_bib7","article-title":"Primary sclerosing cholangitis-inflammatory bowel disease: epidemiology, mortality, and impact of diagnostic sequence","volume":"7","author":"Leung","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cld.2026.04.013_bib8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/00365521.2019.1707277","article-title":"Epidemiology, risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland","volume":"55","author":"Barner-Rasmussen","year":"2020","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cld.2026.04.013_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph17093095","article-title":"Primary sclerosing cholangitis: burden of disease and mortality using data from the national rare diseases registry in Italy","volume":"17","author":"Carbone","year":"2020","journal-title":"Int J Environ Res Publ Health"},{"key":"10.1016\/j.cld.2026.04.013_bib10","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/hep.23678","article-title":"Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden","volume":"52","author":"Lindkvist","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.04.013_bib11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/00365529850166284","article-title":"Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population","volume":"33","author":"Boberg","year":"1998","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cld.2026.04.013_bib12","article-title":"Past, current, and future trends in the prevalence of primary sclerosing cholangitis and inflammatory bowel disease across England (2015\u20132027): a nationwide, population-based study","volume":"44","author":"Crothers","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.cld.2026.04.013_bib13","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/hep.26565","article-title":"Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis","volume":"58","author":"Boonstra","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.04.013_bib14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1471-230X-11-83","article-title":"The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse population","volume":"11","author":"Toy","year":"2011","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2026.04.013_bib15","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cgh.2020.05.061","article-title":"Trends in incidence of autoimmune liver diseases and increasing incidence of autoimmune hepatitis","volume":"19","author":"Lamba","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.04.013_bib16","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/hep.26454","article-title":"Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history","volume":"58","author":"Deneau","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.04.013_bib17","article-title":"Geo-epidemiology and environmental co-variate mapping of primary biliary cholangitis and primary sclerosing cholangitis","volume":"3","author":"Dyson","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cld.2026.04.013_bib18","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.cgh.2013.09.024","article-title":"Effects of coffee consumption, smoking, and hormones on risk for primary sclerosing cholangitis","volume":"12","author":"Andersen","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2026.04.013_bib19","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2020.07.032","article-title":"Inter- and intra-individual variation, and limited prognostic utility, of serum alkaline phosphatase in a trial of patients with primary sclerosing cholangitis","volume":"19","author":"Trivedi","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.04.013_bib20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jhep.2023.02.030","article-title":"Primary sclerosing cholangitis and overlap features of autoimmune hepatitis: a coming of age or an age-ist problem?","volume":"79","author":"Ricciuto","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.04.013_bib21","article-title":"Pruritus is common in primary sclerosing cholangitis, persists over time, and its intensity is associated with disease severity","author":"Hussain","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.04.013_bib22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/hep.26909","article-title":"Pruritus in cholestasis: facts and fiction","volume":"60","author":"Beuers","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.04.013_bib23","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","article-title":"EASL Clinical Practice Guidelines on sclerosing cholangitis","volume":"77","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.04.013_bib24","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1053\/j.gastro.2008.01.042","article-title":"The natural history of small-duct primary sclerosing cholangitis","volume":"134","author":"Bj\u00f6rnsson","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2026.04.013_bib25","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1053\/j.gastro.2017.02.038","article-title":"Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis","volume":"152","author":"Weism\u00fcller\u2217","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2026.04.013_bib26","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1053\/jhep.2001.22131","article-title":"Autoimmune hepatitis\/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study","volume":"33","author":"Gregorio","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.04.013_bib27","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.ebiom.2015.08.041","article-title":"Contrasting pattern of chronic inflammatory bowel disease in primary and autoimmune sclerosing cholangitis","volume":"2","author":"Bjarnason","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.cld.2026.04.013_bib28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jpeds.2021.07.047","article-title":"Sclerosing cholangitis in pediatric inflammatory bowel disease: early diagnosis and management affect clinical outcome","volume":"238","author":"Hensel","year":"2021","journal-title":"J Pediatr"},{"key":"10.1016\/j.cld.2026.04.013_bib29","article-title":"Biliary disease progression in childhood onset autoimmune liver disease: a 30-year follow-up into adulthood","volume":"6","author":"Warner","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cld.2026.04.013_bib30","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001692","article-title":"Understanding hepatopancreatobiliary cancer risks in a population-based primary sclerosing cholangitis-inflammatory bowel disease cohort","author":"Leung","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.04.013_bib31","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.cgh.2017.10.028","article-title":"Primary sclerosing cholangitis is not rare among blacks in a multi-center North American consortium","volume":"16","author":"Goldberg","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2026.04.013_bib32","first-page":"591","article-title":"The Swedish initiative for the study of primary sclerosing cholangitis (SUPRIM)","volume":"16","author":"Cornillet","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.cld.2026.04.013_bib33","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/hep.30237","article-title":"Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease","volume":"69","author":"Muir","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.04.013_bib34","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1111\/liv.14645","article-title":"Prevalence and long-term outcome of sub-clinical primary sclerosing cholangitis in patients with ulcerative colitis","volume":"40","author":"Culver","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2026.04.013_bib35","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1053\/j.gastro.2016.06.021","article-title":"Prevalence of sclerosing cholangitis detected by magnetic resonance cholangiography in patients with long-term inflammatory bowel disease","volume":"151","author":"Lunder","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2026.04.013_bib36","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1053\/jhep.2002.33202","article-title":"Small-duct primary sclerosing cholangitis: a long-term follow-up study","volume":"35","author":"Angulo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.04.013_bib37","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s10620-023-08260-1","article-title":"Primary sclerosing cholangitis limited to intrahepatic bile ducts has distinctly better prognosis","volume":"69","author":"Are","year":"2024","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cld.2026.04.013_bib38","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/hep.30479","article-title":"Factors associated with outcomes of patients with primary sclerosing cholangitis and development and validation of a risk scoring system","volume":"69","author":"Goode","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.04.013_bib39","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bpg.2011.10.003","article-title":"Medical and endoscopic therapy of primary sclerosing cholangitis","volume":"25","author":"Weism\u00fcller","year":"2011","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.cld.2026.04.013_bib40","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jhep.2010.02.030","article-title":"In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival","volume":"53","author":"Rudolph","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.04.013_bib41","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3109\/00365521.2015.1036359","article-title":"Liver transplantation in the Nordic countries - an intention to treat and post-transplant analysis from the Nordic liver transplant registry 1982-2013","volume":"50","author":"Fosby","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cld.2026.04.013_bib43","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0025-6196(11)64614-4","article-title":"A revised natural history model for primary sclerosing cholangitis","volume":"75","author":"Kim","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cld.2026.04.013_bib44","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.04.013_bib45","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1572-0241.2006.00872.x","article-title":"Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study","volume":"102","author":"Tischendorf","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2026.04.013_bib46","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhep.2012.10.013","article-title":"Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis","volume":"58","author":"Al Mamari","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.04.013_bib47","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.cgh.2012.12.032","article-title":"Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis","volume":"11","author":"Lindstr\u00f6m","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.04.013_bib48","first-page":"1292","article-title":"Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis. Aliment","volume":"40","author":"Rupp","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.cld.2026.04.013_bib49","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1111\/liv.13110","article-title":"Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and 1 year later: evaluation of prognostic value","volume":"36","author":"de Vries","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2026.04.013_bib50","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/ajg.2011.156","article-title":"High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis","volume":"106","author":"Eaton","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2026.04.013_bib51","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/j.1365-2036.2011.04863.x","article-title":"High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis","volume":"34","author":"Imam","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2026.04.013_bib52","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/hep.30085","article-title":"Primary sclerosing cholangitis risk estimate tool (PREsTo) predicts outcomes in PSC: a derivation & validation study using machine learning","volume":"71","author":"Eaton","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.04.013_bib53","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1136\/gutjnl-2016-313681","article-title":"A novel prognostic model for transplant-free survival in primary sclerosing cholangitis","volume":"67","author":"Vries","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.cld.2026.04.013_bib54","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jhep.2019.06.012","article-title":"Validation, clinical utility and limitations of the Amsterdam-Oxford model for primary sclerosing cholangitis","volume":"71","author":"Goet","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.04.013_bib55","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/hep.31393","article-title":"The sclerosing cholangitis outcomes in pediatrics (SCOPE) index: a prognostic tool for children","volume":"73","author":"Deneau","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.04.013_bib56","first-page":"169","article-title":"Follow-up magnetic resonance imaging\/3D-magnetic resonance cholangiopancreatography in patients with primary sclerosing cholangitis: challenging for experts to interpret. Aliment","volume":"48","author":"Zenouzi","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.cld.2026.04.013_bib57","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/hep.26620","article-title":"Radiologic course of primary sclerosing cholangitis: assessment by three-dimensional magnetic resonance cholangiography and predictive features of progression","volume":"59","author":"Ruiz","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.04.013_bib58","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1016\/j.cgh.2019.03.013","article-title":"Simple magnetic resonance scores associate with outcomes of patients with primary sclerosing cholangitis","volume":"17","author":"Lemoinne","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.04.013_bib59","article-title":"Development of a prognostic MRCP-Score (DiStrict) for individuals with large-duct primary sclerosing cholangitis","volume":"4","author":"Grigoriadis","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cld.2026.04.013_bib60","first-page":"1366","article-title":"Quantitative MRCP and metrics of bile duct disease over time in patients with primary sclerosing cholangitis: a prospective study. Aliment","volume":"59","author":"Trivedi","year":"2024","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.cld.2026.04.013_bib61","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.dld.2022.10.015","article-title":"A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis","volume":"55","author":"Cristoferi","year":"2023","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cld.2026.04.013_bib62","article-title":"A composite score using quantitative magnetic resonance cholangiopancreatography predicts clinical outcomes in primary sclerosing cholangitis","volume":"5","author":"Vuppalanchi","year":"2023","journal-title":"JHEP Rep Innov Hepatol"},{"key":"10.1016\/j.cld.2026.04.013_bib63","article-title":"Quantitative magnetic resonance cholangiopancreatography metrics are associated with disease severity and outcomes in people with primary sclerosing cholangitis","volume":"4","author":"Cazzagon","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cld.2026.04.013_bib64","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.14309\/ajg.0000000000000461","article-title":"The complementary value of magnetic resonance imaging and vibration-controlled transient elastography for risk stratification in primary sclerosing cholangitis","volume":"114","author":"Cazzagon","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2026.04.013_bib65","first-page":"339A","article-title":"Applicability and prognostic value of histologic scoring systems in primary sclerosing cholangitis","volume":"60","author":"de Vries","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.04.013_bib66","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/hep.28963","article-title":"Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: an international cohort study","volume":"65","author":"de Vries","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.04.013_bib67","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1053\/j.gastro.2013.12.030","article-title":"Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis","volume":"146","author":"Corpechot","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2026.04.013_bib68","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0168-8278(24)00431-8","article-title":"GS-007 prospective validation of the prognostic value of liver stiffness assessed by Fibroscan in primary sclerosing cholangitis: final results of the FICUS study","volume":"80","author":"Chazouill\u00e8res","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.04.013_bib69","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/hep.27825","article-title":"Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis","volume":"62","author":"Vesterhus","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.04.013_bib70","article-title":"Fluctuating biomarkers in primary sclerosing cholangitis: a longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF","volume":"3","author":"Fossdal","year":"2021","journal-title":"JHEP Rep Innov Hepatol"},{"key":"10.1016\/j.cld.2026.04.013_bib71","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000467","article-title":"Serologic extracellular matrix remodeling markers are related to fibrosis stage and prognosis in a phase 2b trial of simtuzumab in patients with primary sclerosing cholangitis","volume":"8","author":"Thorburn","year":"2024","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cld.2026.04.013_bib72","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1136\/gutjnl-2016-312354","article-title":"Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner","volume":"67","author":"Trivedi","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.cld.2026.04.013_bib73","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/gutjnl-2016-311739","article-title":"Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis","volume":"66","author":"Jendrek","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.cld.2026.04.013_bib74","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.cgh.2024.10.005","article-title":"Anti-integrin \u03b1v\u03b26 autoantibodies are increased in primary sclerosing cholangitis patients with concomitant inflammatory bowel disease and correlate with liver disease severity","volume":"23","author":"Bloemen","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.04.013_bib75","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/liv.14326","article-title":"Risk of gallbladder cancer in patients with primary sclerosing cholangitis and radiographically detected gallbladder polyps","volume":"40","author":"van Erp","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2026.04.013_bib76","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.cgh.2024.09.037","article-title":"Incidence of hepatobiliary malignancies in primary sclerosing cholangitis: systematic review and meta-analysis","volume":"23","author":"Souza","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.04.013_bib77","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70312","article-title":"Ultrasound for the detection of gallbladder malignancy in primary sclerosing cholangitis","volume":"45","author":"Altenm\u00fcller","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2026.04.013_bib78","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/HEP.0000000000001351","article-title":"Cirrhosis and age are key determinants of HCC risk in individuals with primary sclerosing cholangitis: a multicenter longitudinal cohort study","volume":"83","author":"Holmer","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.04.013_bib79","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.cgh.2011.02.007","article-title":"Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma","volume":"9","author":"Sinakos","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.04.013_bib80","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jhep.2022.11.011","article-title":"Prospective surveillance for cholangiocarcinoma in unselected individuals with primary sclerosing cholangitis","volume":"78","author":"Villard","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.04.013_bib81","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/hep.29730","article-title":"Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis","volume":"67","author":"Ali","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.04.013_bib82","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/hep.31575","article-title":"Early cholangiocarcinoma detection with magnetic resonance imaging versus ultrasound in primary sclerosing cholangitis","volume":"73","author":"Eaton","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.04.013_bib83","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/HEP.0000000000001314","article-title":"Deep learning analysis of MRI accurately detects early-stage perihilar cholangiocarcinoma in patients with primary sclerosing cholangitis","volume":"83","author":"Singh","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.04.013_bib84","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jhep.2023.02.027","article-title":"Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma","volume":"79","author":"Lapitz","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.04.013_bib85","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cgh.2017.07.023","article-title":"Patients with ulcerative colitis and primary sclerosing cholangitis frequently have subclinical inflammation in the proximal Colon","volume":"16","author":"Krugliak Cleveland","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.04.013_bib86","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1002\/ibd.22938","article-title":"Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease","volume":"18","author":"Boonstra","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cld.2026.04.013_bib87","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/jpn3.12434","article-title":"Intestinal histopathology in pediatric PSC-IBD: characterization of phenotype and assessment of the Nancy Index","volume":"80","author":"Little","year":"2025","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"12","key":"10.1016\/j.cld.2026.04.013_bib88","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/ecco-jcc\/jjac090","article-title":"Increased risk of non-conventional and invisible dysplasias in patients with primary sclerosing cholangitis and inflammatory bowel disease","volume":"16","author":"Zhang","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cld.2026.04.013_bib89","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.02.013","article-title":"Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline","volume":"66","author":"Aabakken","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.04.013_bib90","doi-asserted-by":"crossref","first-page":"E1285","DOI":"10.1055\/a-2437-8102","article-title":"Dye-based chromoendoscopy detects more neoplasia than white light endoscopy in patients with primary sclerosing cholangitis and IBD","volume":"12","author":"Motta","year":"2024","journal-title":"Endosc Int Open"},{"key":"10.1016\/j.cld.2026.04.013_bib91","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.crohns.2013.02.002","article-title":"Natural history of low grade dysplasia in patients with primary sclerosing cholangitis and ulcerative colitis","volume":"7","author":"Venkatesh","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cld.2026.04.013_bib92","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/liv.13548","article-title":"Inflammatory bowel disease with primary sclerosing cholangitis: a Danish population-based cohort study 1977-2011","volume":"38","author":"S\u00f8rensen","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2026.04.013_bib93","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/j.cgh.2020.02.014","article-title":"Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis","volume":"18","author":"Hedin","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.04.013_bib94","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S2468-1253(24)00200-0","article-title":"Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial","volume":"9","author":"Choy","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.04.013_bib95","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1093\/ibd\/izaa317","article-title":"Association of Anti-TNF therapy with increased risk of acute cholangitis in patients with primary sclerosing cholangitis","volume":"27","author":"Kulkarni","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cld.2026.04.013_bib96","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cgh.2019.05.013","article-title":"Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases","volume":"18","author":"Lynch","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.04.013_bib97","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/ecco-jcc\/jjz088","article-title":"Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: a GETAID multicentre cohort Study","volume":"13","author":"Caron","year":"2019","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cld.2026.04.013_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2023.01.014","article-title":"Evaluation of Tofacitinib in primary sclerosing cholangitis and associated colitis: a multicenter, retrospective study","author":"Schregel","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.04.013_bib99","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjae190.1213","article-title":"P1039 an evaluation of Anti-IL23 therapy in primary sclerosing cholangitis associated inflammatory bowel disease","volume":"19","author":"Al-Shakhshir","year":"2025","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cld.2026.04.013_bib100","doi-asserted-by":"crossref","DOI":"10.1007\/s10620-026-09699-8","article-title":"Clinical outcomes in patients with primary sclerosing cholangitis with and without inflammatory bowel disease","author":"Ibrahim","year":"2026","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cld.2026.04.013_bib101","article-title":"Proctocolectomy with permanent ileostomy is associated with improved transplant-free survival in patients with PSC","volume":"8","author":"Mol","year":"2026","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cld.2026.04.013_bib102","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/003655202760373434","article-title":"Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation","volume":"37","author":"Boberg","year":"2002","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2026.04.013_bib103","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/ajg.2016.55","article-title":"Duration of inflammatory bowel disease is associated with increased risk of cholangiocarcinoma in patients with primary sclerosing cholangitis and IBD","volume":"111","author":"Gulamhusein","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2026.04.013_bib104","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/lt.21679","article-title":"A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts","volume":"15","author":"Alabraba","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cld.2026.04.013_bib105","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.jhep.2015.07.005","article-title":"Risk factors for recurrent primary sclerosing cholangitis after liver transplantation","volume":"63","author":"Ravikumar","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.04.013_bib106","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/lt.24350","article-title":"Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: a retrospective multicenter analysis: biliary strictures and PSC recurrence","volume":"22","author":"Hildebrand","year":"2016","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cld.2026.04.013_bib107","first-page":"1","article-title":"Risk factors and prognosis for recurrent primary sclerosing cholangitis after liver transplantation: a Nordic Multicentre Study","author":"Lindstr\u00f6m","year":"2018","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cld.2026.04.013_bib108","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/apt.14828","article-title":"The impact of ileal pouch-anal anastomosis on graft survival following liver transplantation for primary sclerosing cholangitis","volume":"48","author":"Trivedi","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2026.04.013_bib109","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/SLA.0000000000006533","article-title":"Long-term outcomes following colectomy and liver transplantation for inflammatory bowel disease with primary sclerosing cholangitis","volume":"283","author":"Matar","year":"2026","journal-title":"Ann Surg"},{"key":"10.1016\/j.cld.2026.04.013_bib110","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10151-024-02976-6","article-title":"Ileal pouch-anal anastomosis and end ileostomy result in equivalent graft survival following liver transplantation for inflammatory bowel disease-primary sclerosing cholangitis","volume":"28","author":"Schabl","year":"2024","journal-title":"Tech Coloproctol"},{"key":"10.1016\/j.cld.2026.04.013_bib111","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.22891","article-title":"Side chain structure determines unique physiologic and therapeutic properties of norUrsodeoxycholic acid in Mdr2\u2212\/\u2212 mice","volume":"49","author":"Halilbasic","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.04.013_bib112","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1053\/j.gastro.2005.10.018","article-title":"24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice","volume":"130","author":"Fickert","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2026.04.013_bib113","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.04.013_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(25)00310-1","article-title":"LBO-001 norucholic acid for the treatment of primary sclerosing cholangitis: 96-week analysis of a pivotal phase 3 trial","volume":"82","author":"Trauner","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.04.013_bib115","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.14309\/ajg.0000000000001956","article-title":"A randomized, dose-finding, proof-of-concept study of Berberine ursodeoxycholate in patients with primary sclerosing cholangitis","volume":"117","author":"Kowdley","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2026.04.013_bib116","doi-asserted-by":"crossref","DOI":"10.14309\/ajg.0000000000003853","article-title":"Nebokitug, an anti-chemokine (C-C motif) ligand 24 monoclonal antibody, in patients with primary sclerosing cholangitis: a phase 2 study","author":"Bowlus","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2026.04.013_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(25)00404-0","article-title":"Safety and efficacy of elafibranor in primary sclerosing cholangitis: the ELMWOOD phase II randomized-controlled trial","author":"Levy","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.04.013_bib118","article-title":"Phase II INTEGRIS-PSC trial of bexotegrast, an \u03b1v\u03b26\/\u03b1v\u03b21 integrin inhibitor, in primary sclerosing cholangitis","author":"Hirschfield","year":"2025","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2026.04.013_bib119","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.clinre.2018.06.009","article-title":"Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience","volume":"42","author":"Lemoinne","year":"2018","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.cld.2026.04.013_bib120","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.cgh.2018.11.002","article-title":"Statin use is associated with improved outcomes of patients with primary sclerosing cholangitis","volume":"17","author":"Stokkeland","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.04.013_bib121","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/hep.28529","article-title":"Aspirin use and the risk of cholangiocarcinoma","volume":"64","author":"Choi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.04.013_bib122","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjae189","article-title":"Open label vancomycin in primary sclerosing cholangitis-inflammatory bowel disease: improved colonic disease activity and associations with changes in host-microbiome-metabolomic signatures","volume":"19","author":"Quraishi","year":"2025","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cld.2026.04.013_bib123","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.14309\/ajg.0000000000000115","article-title":"Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial","volume":"114","author":"Allegretti","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2026.04.013_bib124","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16181","article-title":"Faecal cytolysin is associated with worse survival in patients with primary sclerosing cholangitis","volume":"45","author":"\u00d6zdirik","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2026.04.013_bib125","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/hep.32773","article-title":"A shared mucosal gut microbiota signature in primary sclerosing cholangitis before and after liver transplantation","volume":"77","author":"Hole","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.04.013_bib126","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1053\/j.gastro.2018.05.034","article-title":"No superiority of stents vs balloon dilatation for dominant strictures in patients with primary sclerosing cholangitis","volume":"155","author":"Ponsioen","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2026.04.013_bib127","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.dld.2010.12.008","article-title":"Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis","volume":"43","author":"Stanich","year":"2011","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cld.2026.04.013_bib128","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/apt.14393","article-title":"Colectomy prior to diagnosis of primary sclerosing cholangitis is associated with improved prognosis in a nationwide cohort study of 2594 PSC-IBD patients","volume":"47","author":"Nordenvall","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2026.04.013_bib129","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1478-3231.2011.02677.x","article-title":"The impact of inflammatory bowel disease post-liver transplantation for primary sclerosing cholangitis","volume":"33","author":"Joshi","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2026.04.013_bib130","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jhep.2017.06.027","article-title":"Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis","volume":"67","author":"Trivedi","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.04.013_bib131","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1093\/ibd\/izz325","article-title":"Activity of inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis predicts poorer clinical outcomes","volume":"26","author":"Peverelle","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cld.2026.04.013_bib132","article-title":"Inflammatory conditions play a role in recurrence of PSC after liver transplantation: an international multicentre study","volume":"4","author":"Visseren","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cld.2026.04.013_bib133","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial","volume":"160","author":"de Vries","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2026.04.013_bib134","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2025-106630","article-title":"Prospective, randomised, placebo-controlled, phase 2 clinical trial assessing the efficacy and safety of oral vancomycin in patients with primary sclerosing cholangitis with\/out inflammatory bowel disease in Italy: study protocol of VanC-IT trial","volume":"16","author":"Cristoferi","year":"2026","journal-title":"BMJ Open"},{"key":"10.1016\/j.cld.2026.04.013_bib135","author":"Carey"},{"key":"10.1016\/j.cld.2026.04.013_bib136","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-095392","article-title":"FAecal micRobiota transplantation in primary sclerosinG chOlangitis (FARGO): study protocol for a randomised, multicentre, phase IIa, placebo-controlled trial","volume":"15","author":"Al-Shakhshir","year":"2025","journal-title":"BMJ Open"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326126000474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326126000474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:06:35Z","timestamp":1785877595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326126000474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":135,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1089326126000474"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2026.04.013","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary Sclerosing Cholangitis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2026.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}